logo

Moleculin Biotech Inc (MBRX)



Trade MBRX now with
  Date
  Headline
2/20/2020 7:51:07 AM Moleculin Reports Positive Independent Report Of No Cardiotoxicity In Annamycin Phase 1 To Date
2/18/2020 7:37:51 AM Moleculin Biotech Announces Final Data From CTCL Clinical Trial Of WP1220 For Cutaneous T-cell Lymphoma
2/5/2020 7:31:20 AM Moleculin To Seek Accelerated FDA Approval And Plans For Pivotal Phase 2 AML Trial
2/3/2020 7:36:08 AM Moleculin Biotech Unveils Successful Completion Of US Phase 1 AML Trial Of Annamycin
12/4/2019 7:32:15 AM Moleculin Announces Addl Positive Interim Results From Phase 1/2 Clinical Studies Of Annamycin In Acute Myeloid Leukemia
11/19/2019 7:31:25 AM Moleculin Announces Positive Trial Data With Safe Delivery Of P-STAT3 Inhibitor And Efficacy In Majority Of Patients
11/12/2019 8:09:45 AM Moleculin Biotech Reports FDA Approval Of IND For Its STAT3 Inhibitor In Emory University Clinical Trial
11/12/2019 7:13:08 AM Moleculin Biotech Q4 Loss Per Share $0.09 Vs Loss $0.08 Last Year
10/22/2019 7:43:40 AM Moleculin Biotech Announces Expansion Of Annamycin Production Commitments
7/10/2019 7:31:32 AM Moleculin Files For New Patents For Annamycin After Receiving FDA Approval Of Fast Track Designation
5/14/2019 7:33:22 AM Moleculin Biotech Q1 Loss Per Share $0.14 Vs Loss $0.08 Last Year
  
 
>